Two Mutations of the Factor IX Gene Including a Donor Splice Consensus Deletion and a Point Mutation in a Dutch Patient with Severe Hemophilia B

Summary

The abnormal factor IX gene of a patient with severe hemophilia B (hemophilia B Ursem) was selected for study. All of the coding and their flanking regions and parts of the 5′- and 3′-untranslated regions of the factor IX gene were amplified from the patient’s genomic DNA by using the polymerase chain reaction (PCR). By analyzing the nucleotide sequence of the PCR products we have identified two mutations in the patient’s factor IX gene, viz. a tetranucleotide deletion (GAGT, nt 6492 to 6495) or (TGAG, nt 6491 to 6494) in the 5′-donor splice site consensus at the exon 2-intron B boundary, and a point mutation at nucleotide 31103 in the catalytic domain (exon 8) of factor IXa, which changes the codon for valine 328 (GTT) to one for isoleucine (ATT). PCR-amplified exon 8 from 45 normal males and 55 normal females had the codon for valine-328. We propose that the deletion within the donor splice-site consensus is the cause of the disease in this individual, whereas the substitution of valine-328 by isoleucine may be a neutral variant which is, at least, very rare in the normal population. In a family study the DNA sequence of the patient’s mother shows both the G to A transition in exon 8 and the 5′-donor splice consensus deletion in intron B in one allele.

• References

• 1 Jackson CM, Nemerson Y. Blood coagulation. Ann Rev Biochem 1980; 49: 765-811
• 2 Thompson AR. Structure, function and molecular defects of factor IX. Blood 1986; 67: 565-572
• 3 Reitsma PH, Bertina RM, Ploos van Amstel JK, Riemens A, Briet E. The putative factor IX gene promoter in hemophilia B Leyden. Blood 1988; 72: 1074-1076
• 4 Reitsma PH, Mandalaki T, Kasper CK, Bertina RM, Briet E. Two novel point mutations correlate with an altered developmental expression of blood coagulation factor IX (Hemophilia B Leyden phenotype). Blood 1989; 73: 743-746
• 5 Diuguid DL, Rabiet MJ, Furie BC, Liebman HA, Furie B. Molecular basis of hemophilia B. A defective enzyme due to an unexpressed propeptide is caused by a point mutation in the factor IX precursor. Proc Natl Acad Sci USA 1986 83. 5803-5807
• 6 Bentley AK, Rees DJ G, Rizza C, Brownlee GG. Defective propeptide processing of blood clotting factor IX caused by mutation of arginine to glutamine at position 4. Cell 1986; 45: 343-348
• 7 Ware J, Liebman H, Kasper C, Graham J, Furie BC, Furie B, Stafford D. Genetic characterization of a hemophilia B variant factor IXsu., Dimas. Blood 1986; 68 suppl 343
• 8 Liddell MB, Lillicrap DP, Peake IR, Bloom AL. Defective propeptide processing and abnormal activation underlie the molecular pathology of factor IX Tioed-y-Rhiw. Br J Haematol 1989; 72: 208-215
• 9 Green PM, Bentley DR, Mibashan RS, Nilsson IM, Giannelli E. Molecular pathology of haemophilia B. EMBO J 1989; 8: 1067-1072
• 10 Davis LM, McGraw RA, Ware JL, Roberts HR, Stafford DW. Factor IX_Alabama point mutation in a clotting protein results in hemophilia B. Blood 1987; 69: 140-143
• 11 Denton PH, Fowlkes DM, Lord ST, Reisner HM. Hemophilia B Durham: a mutation in the tirst EGF-like domain of factor IX that is characterized by polymerase chain reaction. Blood 1988; 72: 1407-1411
• 12 Noyes C, Griffith MJ, Roberts HR, Lundblad R. Identification of the molecular defect in factor IXcnrp.l Hiu: substitution of histidine for arginine at position 145. Proc Natl Acad Sci USA 1983; 80: 4200-4202
• 13 Sakai T, Yoshioka A, Yamamoto K, Niinomi K, Fujimura Y, Fukui H, Miyata T, Iwanaga S. Blood clotting factor IX-Kashihara. Aminoacid substitution of valine-182 by phenylalanine J Biochem 1989 105. 756-759
• 14 Toomey JR, Stafford D, Smithe K. Factor IX_Alabama (arginine 145 to ysteine) is cleaved slowly by factor XIa and has reduced coagulant activity. Blood 1988; 72 suppl (Suppl. 01) 312a
• 15 Huang MN, Kasper CK, Robert HR. Stafford D W High K A. Molecular defect in factor IXn1o, a hemophilia By variant: arg to gln at the carboxyterminal cleavage site of the activation peptide. Blood 1989 73. 718-741
• 16 Geddes VA, LeBonniec BE, Louie GV, Brayer GD, Thompson AR, Mac Gillivray RT A. A moderate form of hemophilia B is caused by a noval mutation in the protease domain of factor IX_Alabama . J Biol Chem 1989; 264: 4689-4697
• 17 Attree O, Vidaud D, Vidaud M, Amselem S, Lavergne JM, Goossens M. Mutations in the catalytic domain of human coagulation factor IX. Rapid characterization by direct genomic sequencing of DNA fragments displaying an altered melting behavior. Genomics 1989; 4: 266-272
• 18 Tsang TC, Bentley DR, Mibashan RS, Giannelli EA. factor IX mutation, verified by direct genomic sequencirg, causes haemophilia B by a novel mechanism. EMBO J 1988; 7: 3009-3016
• 19 Ware J, DaviS L, Frazier D, Bajaj SP, Stafford DW. Genetic defect responsible for the dysfunctional protein: factor IXeng Beach. Blood 1988; 72: 820-822
• 20 Spitzer SG, Pendurthi UR, Kasper CK, Bajaj SP. Molecular defect in factor IX BM Lake Elsinore. Substitution of ala3eO by Val in the catalytic domain. J Biol Chem 1988 263. 10545-10548
• 21 Poort SR, Briet E, Bertina RM, Reitsma PH. A Dutch family with moderately severe hemophilia B (Factor IX_Herde) has a missence mutation identical to that of factor IX_London . Nucleic Acid Res 1989; 17: 3614
• 22 Sugimoto M, Miyata T, Kawabata S, Yoshioka A, Fukui H, Thkahashi H, Iwanaga S. Blood clotting factor IX Niigata Substitution of alanine-390 by valine in the catalytic domain. J Biochem 1988; 104: 878-880
• 23 Rees DJ G, Rizza CR, Brownlee GG. Hemophilia B caused by a point mutation in a donor splice junction of the human factor IX gene. Nature 1985; 316: 643-645
• 24 Brownlee GG. The molecular genetics of haemophilia A and B. J Cell Sci Suppl 1986; 4: 445-458
• 25 Koeberl DD, Bottema CD K, Buerstedde JM, Sommer SS. Functionally important regions of the factor IX gene have a low rate of polymorphism and a high rate of mutation in the dinucleotide CpG. Am J Hum Genet 1989; 45: 448-457
• 26 Matsushita T, Thnimoto M, Yamamoto K, Sugiura I, Hamaguchi M, Thkamatsu J, Saito N. Nucleotide sequence analysis of hemophilia B with the inhibitor phenotype. Blood 1989; 74: 251a
• 27 Giannelli E, Choo KH, Rees DJ G, Boyd Y, Rizza CR, Brownlee GG. Gene deletions in patients with hemophilia B and anti-factor IX antibodies. Nature 1983; 303: 181-182
• 28 Peake IR, Furlong BL, Bloom AL. Carrier detection by direct gene analysis in a family with hemophilia B (factor IX deficiency). Lancet 1984; 242-243
• 29 Bernardi E, Del Senno L, Barbieri R, Buzzoni D, Gambari R, Marchetti G, Conconi E, Panicucci E, Positano M, Pitruzzello S. Gene deletion in an Italian hemophilia B subject. J Med Genet 1985; 22: 305-307
• 30 Chen SH, Yoshitake S, Chance PF, Bray GL, Thompson AR, Scott CR, Kurachi K. An intragenic deletion of the factor IX gene in a family with hemophilia B. J Clin Invest 1985; 76: 2161-2164
• 31 Hassan HJ, Leonardi A, Guerriro R, Chelucci C, Cianetti L, Ciavarella N, Ranieri P, Pilolli D, Peschle C. Hemophilia B with inhibitor: molecular analysis of the subtotal deletion of the factor IX gene. Blood 1985; 66: 728-730
• 32 Bray GL, Thompson AR. Partial factor IX protein in a pedigree with hemophilia B due to a partial gene deletion. J Clin Invest 1986; 77: 1194-1200
• 33 Vidaud M, Chabret C, Gazangel C, Grunebaum L, Cazanave JP, Goossens M. A de novo intragenic deletion of the potential EGF domain of the factor IX gene in a family with severe hemophilia B. Blood 1986; 68: 961-963
• 34 Matthews RJ, Anson DS, Peake IR, Bloom AL. Heterogeneity of the factor IX locus in nine hemophilia B inhibitor patients. J Clin Invest 1987; 79: 746-753
• 35 Schach BG, Yoshitake S, Davie EW. Hemophilia B (factor IX Seattle 2) due to a single nucleotide deletion in the gene for factor IX. J Clin Invest 1987; 80: 1023-1028
• 36 Chen SH, Scott CR, Edson JR, Kurachi K. An insertion within the factor IX gene: hemophilia B_{EI salvador} . Am J Hum Genet 1988; 42: 581-584
• 37 Yoshitake S, Schach BG, Foster DC, Davie EW, Kurachi K. Nucleotide sequence of the gene for human factor IX (antihemophilic factor B). Biochemistry 1985; 24: 3736-3750
• 38 Maniatis T, Fritsch ER, Sambrook J. Molecular Cloning.. A Laboratory Manual Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 1982
• 39 Beaucage SL, Caruthers MH. Deoxynucleoside phosphoramidites: a new class of key intermediates for deoxypolynucleotide synthesis. Tetrahedron Lett 1981; 22: 1859-1865
• 40 Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis KB, Erlich HA. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988; 239: 487-491
• 41 Sanger F, Nicklen S, Coulson AR. DNA sequencing with chainterminating inhibitors. Proc Natl Acad Sci USA 1977; 74: 5463-5467
• 42 Mount SM. A catalogue of splice junction sequences. Nucleic Acids Res 1982; 10: 459-472
• 43 Shapiro MB, Senapathy P. RNA splice junctions of different classes of eukaryotes: sequence statistics and functional implications in gene expression. Nucleic Acids Res 1987; 15: 7155-7175
• 44 Breathnach R, Benoist C, O’Hara K, Gannon R, Chambon P. Ovalbumin gene: evidence for a leader sequence in mRNA and DNA sequences at the exon-intron boundaries. Proc Natl Acad Sci USA 1978; 75: 4853-4857
• 45 Kazazian jr HH, Boehm CD. Molecular basis and prenatal diagnosis of p-thalassemia. Blood 1988; 72: 1107-1116
• 46 Youssoufian H, Kazazian HH, Patel A, Aronis S, Tsiftis G, Hoyer LW, Antonarakis SE. Mild hemophilia A associated with a cryptic donor splice site mutation in intron 4 of the factor VIII gene. Genomics 1988; 2: 32-36